Jennifer Doudna

Jennifer Doudna
Born	Jennifer Anne Doudna (1964-02-19) February 19, 1964 Washington, D.C., U.S.
Occupation	Biochemist
Known for	CRISPR gene editing technology
Notable work	Co-discovery of CRISPR-Cas9 genome editing

Jennifer Anne Doudna (born February 19, 1964) is a distinguished American biochemist recognized for her groundbreaking contributions to CRISPR gene editing and key advancements in biochemistry and genetics. Alongside Emmanuelle Charpentier, she was awarded the 2020 Nobel Prize in Chemistry for creating a revolutionary genome editing technique. She currently occupies the Li Ka Shing Chair Professorship in chemistry as well as molecular and cell biology at the University of California, Berkeley, and has been a Howard Hughes Medical Institute investigator since 1997.

In 2012, Doudna and Charpentier were pioneers in demonstrating that CRISPR-Cas9—enzymes derived from bacterial immune systems—could be harnessed for precise genome editing. This innovation is regarded as one of the most impactful breakthroughs in modern biology. Since then, Doudna has been at the forefront of the "CRISPR revolution," advancing both the development and practical applications of CRISPR-based genome engineering.

Her accolades include the 2000 Alan T. Waterman Award for her research elucidating ribozyme structures through X-ray crystallography, and the 2015 Breakthrough Prize in Life Sciences, which she shared with Charpentier for their work on CRISPR-Cas9 technology. Additional distinctions comprise the Gruber Prize in Genetics (2015), Tang Prize (2016), Canada Gairdner International Award (2016), and Japan Prize (2017). In 2015, she was recognized as one of Time magazine’s 100 most influential figures, and in 2023, she was inducted into the National Inventors Hall of Fame.

The CRISPR-Cas9 system developed by Doudna has transformed molecular biology by providing unprecedented tools with significant promise for treating genetic disorders.

Early life and education

Jennifer Doudna was born on February 19, 1964, in Washington, D.C., to Dorothy Jane (Williams) and Martin Kirk Doudna. Her father earned a PhD in English literature from the University of Michigan, while her mother held a master’s degree in education. When Jennifer was seven years old, her family relocated to Hawaii due to her father’s faculty position at the University of Hawaii at Hilo. During this period, her mother pursued a second master’s degree in Asian history and taught at a local community college.

Raised in Hilo, Hawaii, Doudna's fascination with science began early, influenced by her father’s collection of science books and exposure to James Watson’s The Double Helix. Her enthusiasm for science and mathematics was further encouraged by her tenth-grade chemistry instructor Jeanette Wong and a guest lecturer specializing in cancer cells. She gained hands-on laboratory experience working with mycologist Don Hemmes at the University of Hawaii at Hilo prior to graduating from Hilo High School in 1981.

Doudna pursued undergraduate studies in biochemistry at Pomona College in California. Although she briefly contemplated switching to French during her freshman year, support from a French teacher alongside mentorship from chemistry professors Fred Grieman and Corwin Hansch motivated her to remain committed to science. She conducted research under Sharon Panasenko’s guidance and completed her Bachelor of Arts degree in biochemistry in 1985. Subsequently, she earned her Ph.D. at Harvard Medical School in biological chemistry and molecular pharmacology under Jack W. Szostak’s supervision, finalizing it in 1989 with a dissertation focused on improving the efficiency of self-replicating catalytic RNA.

Career and research

Following the completion of her doctorate, Doudna undertook research fellowships specializing in molecular biology at Massachusetts General Hospital and genetics at Harvard Medical School. Between 1991 and 1994, she was awarded the Lucille P. Markey Postdoctoral Scholarship in Biomedical Science at the University of Colorado Boulder, collaborating with Thomas Cech. By 2022, her scholarly impact is reflected in an h-index of 141 on Google Scholar and 111 on Scopus.

Investigations into ribozyme architecture and activity

In the early stages of her scientific journey, Doudna concentrated on examining the structural and functional properties of RNA enzymes, known as ribozymes. While working in the Szostak laboratory, she successfully redesigned the self-splicing Group I catalytic intron from Tetrahymena into an authentic catalytic ribozyme capable of replicating RNA templates. Acknowledging the difficulties involved in visualizing ribozyme mechanisms, she joined Thomas Cech’s laboratory to crystallize and elucidate the first three-dimensional structure of a ribozyme, enabling comparative analysis with protein enzymes. This initiative began in 1991 and culminated at Yale University in 1996, where she had been appointed assistant professor in the Department of Molecular Biophysics and Biochemistry since 1994.

X-ray crystallography revealing ribozyme active site structure at Yale

During her tenure at Yale, Doudna’s research team successfully crystallized and resolved the three-dimensional configuration of the catalytic core within the Tetrahymena Group I ribozyme. Their findings revealed a cluster of five magnesium ions located in the P4-P6 domain that form a hydrophobic core critical for proper folding—functionally analogous yet chemically distinct from protein cores. Additionally, her group crystallized other ribozymes such as the Hepatitis Delta Virus ribozyme. This pioneering structural work laid the groundwork for subsequent studies on internal ribosome entry sites (IRES) and complexes involving protein-RNA interactions like the signal recognition particle.

In 2000, Doudna was elevated to Henry Ford II Professor of Molecular Biophysics and Biochemistry at Yale and concurrently served as Robert Burns Woodward Visiting Professor of Chemistry at Harvard University during 2000–2001.

Transition to Berkeley

Doudna relocated to the University of California, Berkeley in 2002 to join her husband Jamie Cate as a professor in biochemistry and molecular biology. This position provided her with access to cutting-edge synchrotron facilities at Lawrence Berkeley National Laboratory for sophisticated x-ray diffraction studies.

In 2009, she briefly stepped away from Berkeley to lead discovery research at Genentech but returned after two months to concentrate on CRISPR research, with support from colleague Michael Marletta.

By 2023, Doudna is serving as director of the Innovative Genomics Institute, a collaborative effort between Berkeley and UCSF that she established to advance genome editing technologies targeting critical issues in human health, agriculture, and climate resilience. She holds the Li Ka Shing Chancellor's Professorship in Biomedicine and Health and chairs the Chancellor's Advisory Committee on Biology. Her laboratory’s research centers on elucidating CRISPR-Cas system structures and functions, developing genome editing tools, optimizing delivery strategies for CRISPR-based therapeutics, and refining precise microbiome editing methodologies.

Discovery of CRISPR-Cas9 genome editing technology

Doudna was introduced to the CRISPR technology by Jillian Banfield in 2006. In 2012, she and her team unveiled a technique for precise genome editing utilizing the Cas9 enzyme derived from the Streptococcus bacterial CRISPR immune defense system. This protein functions as RNA-directed molecular scissors that target and cleave viral DNA to block infections. Although CRISPR was initially identified in 1987 and further analyzed by other researchers, Doudna and Emmanuelle Charpentier were pioneers in demonstrating programmable DNA cleavage using various guide RNAs.

With CRISPR's expansion into multicellular organisms, Doudna became a prominent advocate addressing the ethical considerations surrounding genome editing. Their breakthrough has been extended to applications in cell biology, agriculture, and potential therapies for diseases including sickle cell anemia, cystic fibrosis, Huntington's disease, and HIV. While supporting somatic gene editing, Doudna and fellow scientists urged a worldwide pause on clinical germline modifications due to ethical concerns.

The advent of CRISPR transformed DNA editing, triggering significant patent disputes. Both UC Berkeley (Doudna’s institution) and the Broad Institute (headed by Feng Zhang) submitted patent applications; the Broad Institute secured early patents specifically for human cell editing, leading to protracted litigation. Ultimately, U.S. courts upheld Broad’s patents, whereas UC Berkeley retained rights over the broader methodology. In Europe, procedural rulings tended to favor UC Berkeley’s claims.

In 2011, Doudna co-established Caribou Biosciences to bring CRISPR innovations into commercial use. She also co-founded Editas Medicine in 2013 but departed amid legal disagreements and chose not to join CRISPR Therapeutics afterward. Additionally, she played a founding role in Intellia Therapeutics and Scribe Therapeutics—the latter focusing on CasX, a compact next-generation Cas9 enzyme variant.

In 2017, Doudna co-wrote A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution, offering a firsthand narrative of the CRISPR breakthrough aimed at a general readership.

Outside of CRISPR research, Doudna uncovered distinctive strategies employed by the hepatitis C virus for protein synthesis, contributing knowledge that may aid antiviral drug development.

Expressing her vision, Doudna remarked, "I have so much optimism about what CRISPR can do to help cure unaddressed genetic diseases and improve sustainable agriculture," while highlighting the importance of responsible advancement to ensure equitable access to these benefits.

Mammoth Biosciences

In 2017, Doudna co-founded Mammoth Biosciences, a bioengineering startup based in San Francisco. The company secured $23 million during its initial funding round and raised an additional $45 million through a Series B financing in 2020. Mammoth specializes in creating user-friendly biosensing diagnostics targeting healthcare, agriculture, environmental surveillance, biodefense, and related sectors.

COVID-19 response

Beginning in March 2020, Doudna spearheaded initiatives at the Innovative Genomics Institute (IGI) to harness CRISPR technologies against the COVID-19 pandemic. Collaborating with colleagues such as Dave Savage and Robert Tjian, the IGI testing facility processed over half a million samples from UC Berkeley and nearby communities. Meanwhile, Mammoth Biosciences validated a rapid CRISPR-based diagnostic for COVID-19 that delivers quicker results at lower costs compared to conventional qRT-PCR testing methods.

Additional engagements

Doudna established and leads the governance board of the Innovative Genomics Institute, which she co-founded in 2014. She holds positions as a faculty scientist at Lawrence Berkeley National Laboratory (LBNL), senior investigator at the Gladstone Institutes, and adjunct professor at the University of California, San Francisco (UCSF). In 2025, LBNL unveiled a new supercomputer named in her honor to replace the Perlmutter system, aimed at advancing artificial intelligence and scientific research.

She participates on scientific advisory boards for companies she helped create, such as Caribou, Intellia, Mammoth, and Scribe, as well as other organizations including Altos Labs, Isomorphic Labs, Johnson & Johnson, Synthego, Tempus AI, and the Welch Foundation. In 2022, she joined Sixth Street Partners as chief science advisor to assist with investment strategies related to CRISPR technologies.

Personal background

Doudna's first marriage occurred in 1988 with Harvard graduate student Tom Griffin; the couple later divorced. While conducting postdoctoral research at the University of Colorado, she met Jamie Cate; together they worked on crystallizing the Tetrahymena Group I intron P4-P6 catalytic domain. They wed in 2000 and both secured faculty roles at Berkeley in 2002. Cate is a professor at Berkeley specializing in gene-editing yeast for biofuel applications. Their son, born in 2002, is pursuing studies in electrical engineering and computer science at UC Berkeley. The family resides in Berkeley.

Recognitions and distinctions

Doudna was honored with the 1996 Beckman Young Investigators Award and the 2000 Alan T. Waterman Award for her research on ribozyme structures. In 2015, she and Emmanuelle Charpentier received the Breakthrough Prize in Life Sciences for their pioneering work on CRISPR/Cas9 genome editing. Additional accolades include the 2016 Canada Gairdner International Award, Heineken Prize, and shared awards such as the Gruber Prize in Genetics (2015), Tang Prize (2016), Japan Prize (2017), and Albany Medical Center Prize (2017).

In 2018, Doudna earned the NAS Award in Chemical Sciences, Pearl Meister Greengard Prize, an American Cancer Society Medal of Honor, and the Kavli Prize in Nanoscience. She was awarded the 2019 Harvey Prize and the Lui Che Woo Prize for Welfare Betterment. The year 2020 saw her receive the Wolf Prize in Medicine and share the Nobel Prize in Chemistry with Charpentier for their genome editing innovations. In 2025, she was bestowed with the National Medal of Technology and Innovation.

She was elected to prestigious bodies including the National Academy of Sciences (2002), American Academy of Arts and Sciences (2003), National Academy of Medicine (2010), and National Academy of Inventors (2014). Doudna became a fellow of the American Academy of Microbiology in 2015 and was inducted as a Foreign Member of the Royal Society in 2016. Other honors include the Golden Plate Award from the American Academy of Achievement (2017), a Guggenheim Fellowship (2020), and the Association for Molecular Pathology's Award for Excellence in Molecular Diagnostics (2021). Pope Francis appointed her to the Pontifical Academy of Sciences in 2021.

Together with Charpentier, Doudna was listed among Time magazine’s 100 most influential individuals in 2015; she was also a runner-up for Time Person of the Year in 2016 alongside fellow CRISPR researchers. She holds honorary Doctor of Science degrees from USC (2018) and Harvard University (2023).

Related links

• Interview with CRISPR Scientist Discussing the Ethical Implications of Genome Editing. Includes audio and transcript. Fresh Air, NPR, March 8, 2021.